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Rationale 
• Buruli ulcer (BU) mostly in rural areas with limited 
diagnostic means  
• Diagnosis often relies on clinical judgment 
• Imperfect performance of laboratory tests  
• Lack of gold standard  
– PCR? 
– Composite standard of one, or two, positive laboratory tests 
Main objective 
• To establish a score to support clinical 
decision making when a Mycobacterium 
ulcerans infection is suspected. 
Methods 
• Latent class model with results of laboratory tests (2 ZN, 
PCR, culture) 
– Categorization of patients with high, respectively low BU 
probability  
• Selection of variables in the score 
– Univariate analysis of variables associated with high BU probability 
(from LCA) 
– Variables associated with p<0.20 included in multivariate model 
– Variables with OR>2.0 or <0.5 after adjustment included in score 
– Rounding off of coefficient 
• Calculation of sensitivity, specificity and predictive values 
associated with each cut-off of the score 
• Choice of final cut-off 
RESULTS 
Patient flow 
447 screened 
367 included 
364 analysed 
80 excluded 
3 secondary exclusions (no clinical data) 
422 lesions 
379 ulcerative 
41 non-ulcerative 
325 patients 
2 missing lab data 
LCA: 
Latent class model 
BU prevalence 16.1 (12.4 – 20.7) 
Sensitivity Specificity 
ZN Akonolinga 0.72 (0.60,0.85) 0.93 (0.90,0.96) 
ZN CPC 0.65 (0.51,0.80) 1.00 (1.00,1.00) 
PCR 1.00 (0.97,1.00) 0.93 (0.89,0.96) 
Culture 0.46 (0.33,0.59) 0.99 (0.98,1.00) 
BU probability by pattern of test 
response 
Predefined 
treatment 
threshold: 0.7 
 Univariate analysis High BU prob (N=51) Low BU prob (N=274) 
p-value Patient characteristics n % n % 
Age Up to 20 years old 35 68.6 59 21.5 <0.001 
21 to 40 years old 10 19.6 76 27.7 
Over 40 years old 6 11.8 139 50.7 
Gender Male 25 49.0 187 68.3 0.008 
Female 26 51.0 87 31.8 
Median duration of episode (IQR) 8 4 - 28 28 5 - 108 <0.001 
Abnormal vascular examination 3 5.9 67 24.5 0.003 
Abnormal neurological examination 0 0.0 21 7.7 0.04 
Previous topical treatment 28 54.9 183 66.8 0.102 
Previous systemic treatment 27 52.9 196 71.5 0.009 
History of trauma 13 25.5 104 38.0 0.089 
Oedema None 24 47.1 123 45.7 0.157 
Perilesional 21 41.2 80 29.7 
Of the affected limb 6 11.8 56 20.8 
Both lower limbs 0 0.0 10 3.7 
 Univariate analysis High MU prob (N=59) Low MU prob (N=320) 
p-value Lesion characteristics n % n % 
Localisation 0.001 
Upper limb 13 22.0 22 6.9 
Lower limb 42 71.2 280 87.5 
Trunk 4 6.8 18 5.6 
Size <=5 cm 33 55.9 128 40.0 0.075 
>5 to 15 cm 18 30.5 133 41.6 
>15 cm 8 13.6 59 18.4 
Hyposensitivity 3 5.1 7 2.2 0.193 
Induration 14 23.7 104 32.8 0.168 
Adenopathy 7 11.9 82 25.6 0.022 
Pain at rest 26 44.1 192 60.2 0.021 
Undermining 37 62.7 96 30.0 <0.001 
Characteristic smell 17 28.8 22 7.0 <0.001 
Green (pus) 19 32.2 69 21.6 0.075 
 Yellow (fibrinous) 54 91.5 242 75.6 0.007 
 Red (bourgeoning) 41 69.6 268 83.8 0.010 
Variables NOT associated with BU 
(univariate analysis) 
• HIV 
• History of fever 
• Number of lesions 
• BU cases in the vicinity 
• Side of the lesion 
• Traditional treatment 
• Depth of the lesion 
• Suspicion of bone 
involvement 
• Complication 
• Warmth 
• Local prurigo 
• Pain during dressing 
• Lesion edges 
• Exsudate quantity  
• Exsudate quality 
• Black color 
• Pink color 
 
Selection of variables for score 
• OR>2.0 or <0.5 
• Variables dropped: duration of episode, 
topical or systemic treatment, history of 
trauma, vascular anomaly, history of fever, 
red color, black color, green color, localization 
of the lesion, induration, type of oedema, 
undermining, pain at rest, lesion size 
 
Buruli score (short version) 
Buruli score Points 
Characteristic smell +3 
Yellow color (fibrin) +3 
Lesion hyposensitivity +2 
Female +2   
Abnormal neurological examination   -10 
Age above 20 and up to 40 -3 
Age above 40 years -5 
Locoregional adenopathy -2 
ROC curve 
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Area under ROC curve = 0.8660Final model AUC 0.87 (95%CI 0.82 – 0.90) 
Other score (long version) 
• Keeping variables 
with OR>1.5 or 
<0.67 
• Similar AUC 
compared to short 
score 
• No difference in 
terms of patient 
classification 
Buruli score Points 
Characteristic smell +3 
Yellow color (fibrin) +3 
Female +2 
Lesion hyposensitivity +2   
Undermining +1 
Green color +1 
Neurological anomalies   -10 
Age above 20 and below 40 -3 
Age above 40 years -5 
Adenopathy -2 
Pain at rest -1 
Lesion size > 5cm -1 
Definition of cut-offs 
• To exclude BU: negative predictive value >95% 
(95CI>90%) 
– Score <=0: NPV 95.7% (95CI 92.0 – 98.0) 
• To treat BU: positive predictive value >70% 
– Large CI! 
– Score >=5: PPV 69.0% (95%CI 49.2 – 84.7) 
– Score >=6: PPV 70.6% (95%CI 44.0 – 89.7) 
 
Buruli score 
< or = 0 1 to 4 
Intermediate 
probability 
Low 
probability 
PCR 
Negative Positive 
Look for other 
diagnosis 
> or = 5 
High 
probability 
Treat for 
Buruli 
Buruli algorithm 
325 suspects 
< or = 0 1 to 4 
81 Intermediate 
probability 
210 Low 
probability 
PCR 
54 Negative 25 Positive 
264 
Look for other 
diagnosis 
> or = 5 
29 High 
probability 
54 
Treat for 
Buruli 
Applied to study patients 
5 missing values 
2 missing 
Comparison between algorithm 
and latent class model 
  Algorithm Score performance 
BU 
probability 
(LCA) 
BU 
(N=54) 
Not BU 
(N=264) 
Total 
(N=318) 
Sensitivity Specificity 
High 42 9 51 82.4%  
(69.1 – 91.6) 
Low 12 255 267    95.5%  
(92.3 – 97.7) 
PPV: 
77.8% 
NPV: 
96.6% 
Comparison with laboratory tests 
Sensitivity (95CI) Specificity (95CI) 
ZN Ako 0.72 (0.60,0.85) 0.93 (0.90,0.96) 
ZN CPC 0.65 (0.51,0.80) 1 (1.00,1.00) 
PCR 1.00 (0.97,1.00) 0.93 (0.89,0.96) 
Culture 0.46 (0.33,0.59) 0.99 (0.98,1.00) 
Sensitivity (95CI) Specificity (95CI) 
Algorithm 0.82 (0.69,0.92) 0.96 (0.92,0.98) 
Discussion 
• Algorithm based on Buruli score 
– Four times less PCR 
• Sensitivity not perfect (82%), but high NPV (97%) 
– Low BU prevalence in our study 
– Can miss some true Buruli cases 
– Clinicians to reevaluate patient if does not respond 
well to treatment of non-BU 
 
Discussion 
• Performance in other contexts? 
– Very dependent on age and sex 
– Depends on patient selection (BU prevalence) 
• Quality of clinical examination 
– Adenopathy, neurological examination 
• Subjectivity of some parameters in the score 
– Hyposensitivity, smell, undermining, color 
 
 
Limitations 
• Latent class based on laboratory results 
– Patients with no positive test not considered BU 
– Independance between tests not perfect  
• Not very precise definition of BU suspect, shift of 
patient population during study 
• Not sufficient data for non-ulcerative lesions 
Perspectives 
• External validation on external dataset 
• Implementation – validation in Cameroon 
– Sites: Ayos, Akonolinga and Bankim 
– Objectives 
• Reproducibility of the score 
• Performance by non-doctors 
• Impact on delay to treatment, loss-to follow-up 
• Cost-effectiveness? 
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